References
- Von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for Type 1 diabetes. Clin. Exp. Immunol. 172(2), 186–202 (2013).
- Parving HH, Tarnow L, Nielsen FS et al. Cyclosporine nephrotoxicity in Type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 22(3), 478–483 (1999).
- Bottazzo GF, Dean BM, Mcnally JM, Mackay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med. 313(6), 353–360 (1985).
- Itoh N, Hanafusa T, Miyazaki A et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92(5), 2313–2322 (1993).
- Coppieters KT, Dotta F, Amirian N et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term Type 1 diabetes patients. J. Exp. Med. 209(1), 51–60 (2012).
- Couri CE, Oliveira MC, Stracieri AB et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301(15), 1573–1579 (2009).
- Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat. Med. 18(1), 48–53 (2012).
- Huurman VA, Hilbrands R, Pinkse GG et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3(6), e2435 (2008).
- Roep BO, Stobbe I, Duinkerken G et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 48(3), 484–490 (1999).
- Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1692–1698 (2002).
- Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 115(10), 2904–2913 (2005).
- Unger WW, Laban S, Kleijwegt FS, Van Der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 39(11), 3147–3159 (2009).
- Kleijwegt FS, Jansen DT, Teeler J et al. Tolerogenic dendritic cells impede priming of naive CD8(+) T cells and deplete memory CD8(+) T cells. Eur. J. Immunol. 43(1), 85–92 (2013).
- Abreu JR, Martina S, Verrijn Stuart AA et al. CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clin. Exp. Immunol. 170(1), 57–65 (2012).
- Unger WW, Velthuis J, Abreu JRF et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J. Autoimmun. 37(3), 151–159 (2011).
- Roep BO, Solvason N, Gottlieb PA et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes. Sci. Transl Med. 5(191), 191ra182 (2013).
- Velthuis JH, Unger WW, Abreu JRF et al. Simultaneous detection of circulating autoreactive CD8(+) T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 59(7), 1721–1730 (2010).
- Skowera A, Ellis RJ, Varela-Calvino R et al. CTLs are targeted to kill beta cells in patients with Type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118(10), 3390–3402 (2008).
- Mallone R, Roep BO. Biomarkers for immune intervention trials in type 1 diabetes. Clin. Immunol. (2013).
- Roep BO, Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from Type 1 diabetes. Nat. Rev. Immunol. 10(2), 145–152 (2010).